Metronidazole.
Metronidazole has proven to be a useful and inexpensive antibiotic for the treatment of T. vaginalis and bacterial vaginosis. Few alternatives exist for these two specific indications, and metronidazole will continue to play a primary role in therapy. Oral metronidazole continues to be a very inexpensive alternative to oral vancomycin for the treatment of C. difficile-induced pseudomembranous colitis. For the treatment of moderate to severe mixed aerobic/anaerobic pelvic infections, metronidazole should be considered secondarily in patients who have failed other multiple- or single-drug regimens or in patients who are infected. with anaerobic organisms resistant to other commonly used agents including clindamycin, cefoxitin, cefotetan, or ampicillin/sulbactam. Metronidazole is not a first line drug of choice for antibiotic prophylaxis in obstetric and gynecologic patients.
Hager
W D
WD
Department of Obstetrics and Gynecology, University of Kentucky School of Medicine, Lexington.
Rapp
R P
RP
D001424:Bacterial Infections / Q000188:drug therapy*; D003365:Costs and Cost Analysis; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D008795:Metronidazole / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy*; D014247:Trichomonas Vaginitis / Q000188:drug therapy; D016585:Vaginosis, Bacterial / Q000188:drug therapy
D008795:Metronidazole